Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Chromadex Corp CS (CDXC)

Chromadex Corp CS (CDXC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 421,634
  • Shares Outstanding, K 76,383
  • Annual Sales, $ 83,570 K
  • Annual Income, $ -4,940 K
  • EBIT $ 0 M
  • EBITDA $ 1 M
  • 60-Month Beta 2.16
  • Price/Sales 5.13
  • Price/Cash Flow N/A
  • Price/Book 12.47

Options Overview Details

View History
  • Implied Volatility 91.94% ( -2.25%)
  • Historical Volatility 55.02%
  • IV Percentile 44%
  • IV Rank 12.06%
  • IV High 648.82% on 08/08/24
  • IV Low 15.54% on 08/14/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 22
  • Volume Avg (30-Day) 167
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 4,794
  • Open Int (30-Day) 7,361

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.02
  • Number of Estimates 2
  • High Estimate 0.04
  • Low Estimate 0.00
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.21 +4.99%
on 12/24/24
7.83 -30.14%
on 12/02/24
-2.25 (-29.15%)
since 11/29/24
3-Month
3.18 +72.01%
on 10/10/24
7.97 -31.40%
on 11/29/24
+1.82 (+49.86%)
since 09/30/24
52-Week
1.36 +302.21%
on 01/23/24
7.97 -31.40%
on 11/29/24
+4.04 (+282.52%)
since 12/29/23

Most Recent Stories

More News
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex

For Immediate ReleaseChicago, IL – December 26, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and...

CDXC : 5.47 (-0.91%)
ADMA : 17.31 (-0.80%)
TARS : 56.33 (+2.42%)
STOK : 10.76 (-2.71%)
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow

The biotech sector witnessed a see-saw performance in 2024. While the year started on a positive note, much of the gains slowed down in the second half of 2024. The downside in the second half was due...

CDXC : 5.47 (-0.91%)
ADMA : 17.31 (-0.80%)
TARS : 56.33 (+2.42%)
STOK : 10.76 (-2.71%)
Insider Sale: Director at $CDXC (CDXC) Sells 37,161 Shares

Frank L Jr Jaksch, a director at $CDXC ($CDXC), sold 37,161 shares of the company on 12-13-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 13.2% of their...

CDXC : 5.47 (-0.91%)
Insider Purchase: Chief Financial Officer of $CDXC (CDXC) Buys 2,907 Shares

Ozan Pamir, the Chief Financial Officer of $CDXC ($CDXC), bought 2,907 shares of the company on 11-22-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...

CDXC : 5.47 (-0.91%)
5 Stocks With Recent Price Strength to Tap Wall Street Rally

U.S. stock markets started November, adding more steam to the ongoing rally. The primary reason was the anticipation of Donald Trump becoming the 47th president of the country. On Nov 5, Trump clinched...

CORT : 50.87 (-3.05%)
SEZL : 248.40 (-6.29%)
CDXC : 5.47 (-0.91%)
TILE : 24.74 (-0.92%)
BGC : 8.91 (-2.09%)
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, May 10, 2023 at 4:30 p.m. ET to discuss...

CDXC : 5.47 (-0.91%)
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results

ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2022 financial results.

CDXC : 5.47 (-0.91%)
ChromaDex to Participate at the 35th Annual ROTH Capital Partners Conference on March 13, 2023

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced that senior management will participate at the 35 th annual ROTH Capital Partners...

CDXC : 5.47 (-0.91%)
ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 8, 2023 at 4:30 p.m. ET to...

CDXC : 5.47 (-0.91%)
ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, holds an exclusive license from Queen’s University Belfast for methods of making nicotinamide riboside (NR) and...

CDXC : 5.47 (-0.91%)

Business Summary

ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is...

See More

Key Turning Points

3rd Resistance Point 5.84
2nd Resistance Point 5.74
1st Resistance Point 5.63
Last Price 5.47
1st Support Level 5.42
2nd Support Level 5.33
3rd Support Level 5.22

See More

52-Week High 7.97
Last Price 5.47
Fibonacci 61.8% 5.45
Fibonacci 50% 4.67
Fibonacci 38.2% 3.89
52-Week Low 1.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar